Cargando…
Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States
Detection of SARS-CoV-2 infections to date has relied heavily on RT-PCR testing. However, limited test availability, high false-negative rates, and the existence of asymptomatic or sub-clinical infections have resulted in an under-counting of the true prevalence of SARS-CoV-2. Here, we show how infl...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319260/ https://www.ncbi.nlm.nih.gov/pubmed/32571980 http://dx.doi.org/10.1126/scitranslmed.abc1126 |
_version_ | 1783551019748163584 |
---|---|
author | Silverman, Justin D. Hupert, Nathaniel Washburne, Alex D. |
author_facet | Silverman, Justin D. Hupert, Nathaniel Washburne, Alex D. |
author_sort | Silverman, Justin D. |
collection | PubMed |
description | Detection of SARS-CoV-2 infections to date has relied heavily on RT-PCR testing. However, limited test availability, high false-negative rates, and the existence of asymptomatic or sub-clinical infections have resulted in an under-counting of the true prevalence of SARS-CoV-2. Here, we show how influenza-like illness (ILI) outpatient surveillance data can be used to estimate the prevalence of SARS-CoV-2. We found a surge of non-influenza ILI above the seasonal average in March 2020 and showed that this surge correlated with COVID-19 case counts across states. If 1/3 of patients infected with SARS-CoV-2 in the US sought care, this ILI surge would have corresponded to more than 8.7 million new SARS-CoV-2 infections across the US during the three-week period from March 8 to March 28, 2020. Combining excess ILI counts with the date of onset of community transmission in the US, we also show that the early epidemic in the US was unlikely to have been doubling slower than every 4 days. Together these results suggest a conceptual model for the COVID-19 epidemic in the US characterized by rapid spread across the US with over 80% infected patients remaining undetected. We emphasize the importance of testing these findings with seroprevalence data and discuss the broader potential to use syndromic surveillance for early detection and understanding of emerging infectious diseases. |
format | Online Article Text |
id | pubmed-7319260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Association for the Advancement of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-73192602020-06-29 Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States Silverman, Justin D. Hupert, Nathaniel Washburne, Alex D. Sci Transl Med Reports Detection of SARS-CoV-2 infections to date has relied heavily on RT-PCR testing. However, limited test availability, high false-negative rates, and the existence of asymptomatic or sub-clinical infections have resulted in an under-counting of the true prevalence of SARS-CoV-2. Here, we show how influenza-like illness (ILI) outpatient surveillance data can be used to estimate the prevalence of SARS-CoV-2. We found a surge of non-influenza ILI above the seasonal average in March 2020 and showed that this surge correlated with COVID-19 case counts across states. If 1/3 of patients infected with SARS-CoV-2 in the US sought care, this ILI surge would have corresponded to more than 8.7 million new SARS-CoV-2 infections across the US during the three-week period from March 8 to March 28, 2020. Combining excess ILI counts with the date of onset of community transmission in the US, we also show that the early epidemic in the US was unlikely to have been doubling slower than every 4 days. Together these results suggest a conceptual model for the COVID-19 epidemic in the US characterized by rapid spread across the US with over 80% infected patients remaining undetected. We emphasize the importance of testing these findings with seroprevalence data and discuss the broader potential to use syndromic surveillance for early detection and understanding of emerging infectious diseases. American Association for the Advancement of Science 2020-06-22 /pmc/articles/PMC7319260/ /pubmed/32571980 http://dx.doi.org/10.1126/scitranslmed.abc1126 Text en Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). http://creativecommons.org/licenses/by/4.0/ https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited. |
spellingShingle | Reports Silverman, Justin D. Hupert, Nathaniel Washburne, Alex D. Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States |
title | Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States |
title_full | Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States |
title_fullStr | Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States |
title_full_unstemmed | Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States |
title_short | Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States |
title_sort | using influenza surveillance networks to estimate state-specific prevalence of sars-cov-2 in the united states |
topic | Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7319260/ https://www.ncbi.nlm.nih.gov/pubmed/32571980 http://dx.doi.org/10.1126/scitranslmed.abc1126 |
work_keys_str_mv | AT silvermanjustind usinginfluenzasurveillancenetworkstoestimatestatespecificprevalenceofsarscov2intheunitedstates AT hupertnathaniel usinginfluenzasurveillancenetworkstoestimatestatespecificprevalenceofsarscov2intheunitedstates AT washburnealexd usinginfluenzasurveillancenetworkstoestimatestatespecificprevalenceofsarscov2intheunitedstates |